Marco Chacón

Dr. Marco Chacón is the Non-executive Chairman of the Board for The Center for Breakthrough Medicines and the Founder and former Chairman of Paragon Bioservices, Inc., a CDMO that specialized in process development and GMP manufacturing of viral vectors for gene therapy. In April of 2019 Paragon Bioservices, Inc. entered into a definitive agreement of sale for $1.2 billion with Catalent. Chacón is the Founder and President of IRAZÚ Bio-Holdings LLC., a company dedicated to developing indications that promote survival, prevent disease and improve quality of life for the elderly. The company is also developing technology in the fields of immuno-oncology and gene therapy. Formerly, Chacón served as Assistant Vice President of Industry Alliances at the University of Maryland, Baltimore. His educational background includes a Bachelor of Science degree from Youngstown State University and a Ph.D. in Nutritional Sciences from the University of Maryland. He currently serves on the Board of Trustees of the University of Maryland Foundation and was appointed in 2016 to the Life Sciences Advisory Board by Governor Lawrence J. Hogan, Jr. Additionally, Dr. Chacón is the founding chair of The Board of Visitors of the University of Maryland Graduate School.